Acrobiosystems Co.,Ltd.: what insiders have been doing
This page follows insider dealings at Acrobiosystems Co.,Ltd. as filed with SSE / SZSE (CSRC), a company from the Health Care sector. 1 insider has disclosed 2 filings since 5 November 2025.
No insider bought on the market over the period, while 1 insider filed 2 sales totalling €82k. At €43k, the sale published on 3 December 2025 by 苗景赟 is the largest of the period.
Across the 519 companies tracked on its exchange, the median is 2 filings; at 2 filings, this issuer sits right on that mark. The full history, which starts in 2025, counts no purchases against 4 sales.
Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleAnalyst consensus: bullish or bearish?
Analysts rate Acrobiosystems Co.,Ltd. Buy (bullish), based on 4 analysts. Average price target: CN¥87.38.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 5,900 shares48.0% of flowA股XSHESZSE:173000009867117900
- 6,300 shares52.0% of flowA股XSHESZSE:173000009860701820
- 9,300 shares42.7% of flowA股XSHESZSE:173000009628394560
- 11,800 shares57.3% of flowA股XSHESZSE:173000009625471900
4 of 4 declarations
About Acrobiosystems Co.,Ltd.
百普赛斯 is a company operating in the healthcare and pharmaceutical sector, listed on the XSHE market. It specializes in the development and commercialization of pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
